Splicing-Disrupting Mutations in Inherited Predisposition to Solid Pediatric Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Hereditary cancer in children was previously underestimated, with recent data indicating germline mutations in cancer predisposition genes in at least 10% of pediatric cancer cases.
• Splicing alterations represent a significant proportion of pathogenic variants linked to hereditary cancer risk.
• RNA splicing is vital for cellular processes, and its dysregulation is implicated in numerous human cancers, particularly pediatric solid tumors.

Purpose of the Study:

• To review germline splicing-disrupting mutations in pediatric solid tumors.
• To highlight the growing importance of pathogenic splice variants in pediatric cancer for personalized therapy development.
• To discuss therapeutic strategies for aberrant splicing and methods to enhance diagnostic yield.

Main Methods:

• Literature review focusing on germline splicing mutations in pediatric solid tumors.
• Analysis of current understanding of RNA splicing in cancer predisposition.
• Examination of emerging therapeutic approaches and diagnostic advancements.

Main Results:

• Germline splicing mutations are a key factor in pediatric solid tumors, challenging previous prevalence estimates.
• Identification of specific hereditary cancer genes susceptible to splicing mutations contributing to pediatric cancers.
• Recognition of splice variants as a critical area for personalized pediatric cancer treatment.

Conclusions:

• Germline splicing mutations are a significant and growing area of research in pediatric solid tumors.
• Advances in understanding splicing offer new avenues for targeted therapies and improved diagnostics.
• Personalized treatment strategies for pediatric hereditary cancer can be enhanced by focusing on splice variants.